Pharma major Novartis falls 10% after three drug trial setbacks
pharma_trial_failureGlobalCNBC8 Sept, 07:51 UTC
Context
Pharma major Novartis falls 10% after three drug trial setbacks CNBC Novartis Sees Avidity Drug Fail in Third Setback in a Week Bloomberg.com Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints BioSpace Novartis RNA drug falls short in rare muscle disease study BioPharma Dive Novartis twin drug trial setbacks pile pressure on pipeline, CEO Reuters
What it means
Causal chain
No clear market signal
How to read a signal
- Severity
- the event's market impact, 1–5
- Direction
- ↑ / ↓ likely price move for the asset
- Exp. move
- the size of the abnormal move we'd expect if the call plays out — not a claim a move will happen:Most flagged events don't move beyond noise; those count against us (see the track record).Ssmall<1%Mmoderate1–5%Llarge>5%
- Timeframe
- the window we measure over:1dshort5dmedium21dlong
- Conviction
- how well-established the directional call is (textbook → speculative) — not a guaranteed outcome:lowaveragestrong
Get the next signal the moment it breaks.
The full live feed, asset filters, and alerts — free.
Sign up free →Not investment advice · for informational purposes only. Generated 9 Sept, 10:48 UTC